<DOC>
	<DOCNO>NCT01096667</DOCNO>
	<brief_summary>MK-8835-042 ( B1521004 ) design assess safety efficacy investigational drug , ertugliflozin ( MK-8835 , PF-04971729 ) , participant type 2 diabetes hypertension . Participants study receive 1 5 treatment 1 month include 1 treatment approve drug - hydrochlorothiazide ( HCTZ ) .</brief_summary>
	<brief_title>Study Safety Efficacy Of Ertugliflozin ( PF-04971729 , MK-8835 ) In Participants With Type 2 Diabetes And Hypertension ( MK-8835-042 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>Patients type 2 diabetes hypertension Medically stable On least 1 ( 2 ) oral diabetes drug And 2 medicine blood pressure control Patients type 1 diabetes Heart attack Stroke Uncontrolled blood pressure Significant kidney disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>type 2 diabetes</keyword>
	<keyword>hypertension</keyword>
	<keyword>ambulatory blood pressure monitoring</keyword>
</DOC>